IP Library › Granted Patent US 10,166,230
Granted Patent B2
US 10,166,230 · App. 14/583,275 · Granted Jan 1, 2019

Treatment of vasomotor symptoms

Inventors: Vladimir Hanes (Tarrytown, NY); Anna Elizabeth Verbeek (Sandy Hook, CT)
A61K31/496A61P15/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,166,230
App. No.
14/583,275
Granted
Jan 1, 2019
Kind
B2
Abstract

The invention relates to a method for the treatment of vasomotor symptoms comprising the administration of a therapeutically effective amount of flibanserin.

Claims (17)

1. A method for the treatment of vasomotor symptoms associated with menopause comprising the administration to a patient in need of such treatment a therapeutically effective amount of flibanserin, or a pharmacologically acceptable acid addition salt, hydrate or solvate, thereof, wherein said vasomotor symptoms are selected from the group consisting of night sweats, mood swings, and irritability.

2. The method according to claim 1 , wherein the vasomotor symptoms are night sweats.

3. The method according to claim 1 , wherein the vasomotor symptoms are mood swings.

4. The method according to claim 1 , wherein the vasomotor symptoms are irritability.

5. The method according to claim 1 , wherein menopause is naturally occurring.

6. The method according to claim 1 , wherein menopause is surgically induced.

7. The method according to claim 1 , wherein menopause is iatrogenic induced.

8. The method according to claim 1 , wherein menopause is associated with the use of medication, radiation, or chemotherapeutic agents.

9. The method according to claim 1 , wherein the flibanserin is administered as a pharmaceutically acceptable acid addition salt selected from the salts formed by succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid, citric acid, and mixtures thereof.

10. The method according to claim 1 , wherein the patient is a menopausal woman.

11. The method according to claim 1 , wherein the patient is a postmenopausal woman.

12. The method according to claim 1 , wherein the patient is a perimenopausal woman.

13. The method according to claim 1 , wherein the flibanserin is administered in a dose range between 0.1 to 400 mg per day.

14. The method according to claim 1 , wherein the flibanserin is administered in a dose range between 1.0 and 300 mg per day.

15. The method according to claim 1 , wherein the flibanserin is administered in a dose range between 2 and 200 mg per day.

16. The method according to claim 1 , wherein the flibanserin is administered in a dose range between 0.01 to 100 mg per day.

17. The method according to claim 1 , wherein the flibanserin is administered in a dose range between 0.1 to 50 mg per day.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY INTEREST Recorded Apr 13, 2023
From: SPROUT PHARMACEUTICALS, INC.
To: HOLLAND, ANNE; MCGLOTHLIN, SANDRA
Reel/Frame 063320/0136 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Sep 9, 2022
From: BARCLAYS BANK PLC
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061402/0194 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Sep 9, 2022
From: THE BANK OF NEW YORK MELLON
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061402/0236 →
SECURITY INTEREST Recorded Feb 25, 2021
From: SPROUT PHARMACEUTICALS, INC.
To: GOODRICH, BRAXTON; WHITEHEAD, ROBERT
Reel/Frame 055407/0810 →
SECURITY INTEREST Recorded Jul 19, 2017
From: SPROUT PHARMACEUTICALS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0950 →
SECURITY AGREEMENT Recorded Dec 21, 2015
From: SPROUT PHARMACEUTICALS, INC., AS GRANTOR; UNILENS VISION INC., AS GRANTOR; COMMONWEALTH LABORATORIES, LLC, AS GRANTOR; SYNERGETICS USA, INC., AS GRANTOR
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 037357/0490 →
Continuity (4)
Continuation 13847683 · Mar 20, 2013
Continuation 12675231
Provisional Application 60971605 · Sep 12, 2007
Related Publication 20150250783A1 · Sep 10, 2015